Agios

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.

About AGIO

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. 

CEO
Brian M. Goff
CEOBrian M. Goff
Employees
540
Employees540
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2007
Founded2007
Employees
540
Employees540

AGIO Key Statistics

Market cap
1.65B
Market cap1.65B
Price-Earnings ratio
-3.82
Price-Earnings ratio-3.82
Dividend yield
Dividend yield
Average volume
897.01K
Average volume897.01K
High today
$27.75
High today$27.75
Low today
$26.49
Low today$26.49
Open price
$26.51
Open price$26.51
Volume
659.90K
Volume659.90K
52 Week high
$46.00
52 Week high$46.00
52 Week low
$22.24
52 Week low$22.24

Stock Snapshot

The current Agios(AGIO) stock price is $27.68, with a market capitalization of 1.65B. The stock trades at a price-to-earnings (P/E) ratio of -3.82.

During the trading session on 2026-06-04, Agios(AGIO) shares reached a daily high of $27.75 and a low of $26.49. At a current price of $27.68, the stock is +4.5% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 659.9K, compared to an average daily volume of 897.01K.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

The stock's 52-week range extends from a low of $22.24 to a high of $46.00.

AGIO News

TipRanks 2d
Agios Pharma Kept at Hold as Analyst Weighs Cevidoplenib Opportunity Against Execution Risks; $32 Price Target Reaffirmed

Analyst Salveen Richter from Goldman Sachs maintained a Hold rating on Agios Pharma and keeping the price target at $32.00. Unlock trusted, data-backed investi...

TipRanks 3d
Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

Agios Pharmaceuticals (AGIO) announced an agreement with Oscotec, headquartered in South Korea, to license the exclusive global rights to cevidoplenib, an oral...

TipRanks 6d
Agios Extends Mitapivat into Pediatric Thalassemia, Opening a New Long-Term Growth Path

Agios Pharmaceuticals (AGIO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analy...

Analyst ratings

70%

of 10 ratings
Buy
70%
Hold
30%
Sell
0%

People also own

Based on the portfolios of people who own AGIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.